• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异体造血干细胞移植受者的严重急性呼吸综合征冠状病毒 2 信使 RNA 疫苗：免疫原性和反应原性。

Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity.

机构信息

Brigham and Women's Hospital, Boston, Massachusetts, USA.

Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

出版信息

Clin Infect Dis. 2022 Aug 24;75(1):e920-e923. doi: 10.1093/cid/ciab930.

DOI:10.1093/cid/ciab930
PMID:34726754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8689898/
Abstract

The severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine-induced humoral response and reactogenicity profile are described in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Findings showed that 75.0% (by Simoa assay) or 80.0% (by Roche assay) of the HSCT cohort had a positive antibody response on series completion, compared with 100% in the healthy cohort.

摘要

这项研究描述了在异基因造血干细胞移植（HSCT）受者中，严重急性呼吸综合征冠状病毒 2 信使 RNA 疫苗诱导的体液免疫反应和不良反应特征。研究结果显示，在完成系列接种后，HSCT 队列中 75.0%（通过 Simoa 检测）或 80.0%（通过罗氏检测）的患者出现了阳性抗体反应，而健康队列中的这一比例为 100%。

相似文献

1
Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity.异体造血干细胞移植受者的严重急性呼吸综合征冠状病毒 2 信使 RNA 疫苗：免疫原性和反应原性。
Clin Infect Dis. 2022 Aug 24;75(1):e920-e923. doi: 10.1093/cid/ciab930.
2
[COVID-19 vaccination for allogeneic hematopoietic stem cell recipients].[异基因造血干细胞受体的新冠病毒疫苗接种]
Rinsho Ketsueki. 2022;63(9):1067-1077. doi: 10.11406/rinketsu.63.1067.
3
Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.异基因造血干细胞受者接种一剂或两剂 COVID-19 疫苗加强针后强烈的 SARS-CoV-2 T 细胞反应。
Cells. 2022 Sep 27;11(19):3010. doi: 10.3390/cells11193010.
4
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.造血干细胞移植受者接种 SARS-CoV-2 疫苗后针对 SARS-CoV-2 的抗体检测：来自西班牙造血干细胞移植和细胞治疗组的前瞻性调查。
Am J Hematol. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. Epub 2021 Nov 2.
5
Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?异体造血干细胞移植受者接种第三剂 SARS-CoV-2 疫苗有效吗？
Br J Haematol. 2023 Apr;201(1):9-10. doi: 10.1111/bjh.18591. Epub 2022 Dec 7.
6
Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients.异体造血干细胞移植受者中 SARS-CoV-2 免疫衰减的决定因素。
J Hematol Oncol. 2022 Mar 18;15(1):27. doi: 10.1186/s13045-022-01250-2.
7
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.SARS-CoV-2 疫苗免疫原性减弱与干细胞移植受者的风险因素：一项荟萃分析。
Blood Adv. 2023 Sep 26;7(18):5624-5636. doi: 10.1182/bloodadvances.2023010349.
8
Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients.肝移植受者接种 2 剂 BNT162b2 mRNA COVID-19 疫苗后的体液免疫反应。
Clin Gastroenterol Hepatol. 2022 Jul;20(7):1534-1541.e4. doi: 10.1016/j.cgh.2022.01.012. Epub 2022 Jan 20.
9
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.B 细胞发育不全是异基因造血干细胞移植受者接受 BNT162b2 mRNA SARS-CoV-2 疫苗接种后体液免疫反应不良的最强预测标志物。
Transplant Cell Ther. 2022 May;28(5):279.e1-279.e4. doi: 10.1016/j.jtct.2022.02.018. Epub 2022 Feb 24.
10
Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.异基因造血干细胞移植受者使用紧急授权的 SARS-CoV2 疫苗的安全性和耐受性。
Transplant Cell Ther. 2021 Nov;27(11):938.e1-938.e6. doi: 10.1016/j.jtct.2021.07.008. Epub 2021 Jul 15.

引用本文的文献

1
Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects.2019冠状病毒病疫苗接种对癌症患者的影响：安全性、有效性及长期影响
Support Care Cancer. 2025 Aug 4;33(8):753. doi: 10.1007/s00520-025-09783-1.
2
Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference.弱势群体中疫苗安全性和有效性的生物标志物：第四届国际精准疫苗会议的经验教训
Vaccine. 2025 Jan 1;43(Pt 2):126477. doi: 10.1016/j.vaccine.2024.126477. Epub 2024 Nov 28.
3
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.癌症患者和接受 HSCT 或 CAR-T 治疗患者的 COVID-19 疫苗接种：免疫反应、真实世界疗效以及对未来的影响。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S55-S69. doi: 10.1093/infdis/jiad174.
4
SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients.造血干细胞移植受者中新型冠状病毒2型疫苗诱导的免疫反应
Open Forum Infect Dis. 2023 Jul 10;10(7):ofad349. doi: 10.1093/ofid/ofad349. eCollection 2023 Jul.
5
Robust spike-specific CD4 and CD8 T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study.在接受 SARS-CoV-2 疫苗接种的造血细胞移植受者中，具有稳健的刺突特异性 CD4 和 CD8 T 细胞应答：一项前瞻性队列研究。
Front Immunol. 2023 Jul 7;14:1210899. doi: 10.3389/fimmu.2023.1210899. eCollection 2023.
6
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.SARS-CoV-2 疫苗免疫原性减弱与干细胞移植受者的风险因素：一项荟萃分析。
Blood Adv. 2023 Sep 26;7(18):5624-5636. doi: 10.1182/bloodadvances.2023010349.
7
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era.COVID-19 时代的异基因造血干细胞移植。
Front Immunol. 2023 Feb 22;14:1100468. doi: 10.3389/fimmu.2023.1100468. eCollection 2023.
8
Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.供者和受者 SARS-CoV-2 疫苗接种或感染对造血细胞移植后免疫的影响。
Transplant Cell Ther. 2023 May;29(5):337.e1-337.e5. doi: 10.1016/j.jtct.2023.01.025. Epub 2023 Feb 2.
9
Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. 关于造血细胞移植和嵌合抗原受体 T 细胞受者的 2019 年冠状病毒病疫苗接种的常见问题解答（来自美国移植和细胞治疗学会与美国血液学会）。
Transplant Cell Ther. 2023 Jan;29(1):10-18. doi: 10.1016/j.jtct.2022.10.010. Epub 2022 Oct 21.
10
Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies.三剂次mRNA新冠疫苗基础免疫系列在淋巴系统恶性肿瘤患者中的免疫原性
Open Forum Infect Dis. 2022 Aug 16;9(8):ofac417. doi: 10.1093/ofid/ofac417. eCollection 2022 Aug.